showed TIGIT expression within the tumor microenvironment of the melanoma B16F10 tumor model (12) and other tumor models such as CT26 (47), EMT6 breast carcinoma (48), GL261 glioblastoma (49), A20 lymphoma (50) have been used to study the effect of anti-TIGIT-blocking mAbs. This evidence concerns the gene TIGIT and lymphoma.